Bezos, Elon Musk and Zuckerberg Betting Big on S.C.G.
The "Black Box" Device Bringing the Age of the Smartphone to an End.
Learn More
Jeffrey Robert Ajer, insider at BioMarin Pharmaceutical
Jeffrey Robert Ajer Insider Alerts

Get notified the next time Jeffrey Robert Ajer buys or sells BioMarin Pharmaceutical stock. Enter your email address below to get our daily insider buying and selling report.

Jeffrey Robert Ajer Insider Information

Jeff Ajer joined BioMarin in August 2005 and currently serves as our Executive Vice President and Chief Commercial Officer. From October 2012 to January 2014, Mr. Ajer served as our Senior Vice President and Chief Commercial Officer. From April 2009 to October 2012, Mr. Ajer served as our Vice President, Commercial Operations, The Americas, where he had responsibility for commercial operations throughout the Americas and led product marketing, reimbursement, and sales operations for BioMarin. Prior to joining BioMarin, Mr. Ajer served in various roles at Genzyme Corporation (Genzyme) beginning in November 2003, most recently as Vice President, Global Transplant Operations from December 2004 to August 2005. Mr. Ajer’s experience prior to Genzyme includes roles in sales, marketing and operations at SangStat Medical Corporation and ICN Pharmaceuticals. Mr. Ajer received both a B.S. in chemistry and an M.B.A. from the University of California, Irvine. Mr. Ajer is currently a director of Nektar Therapeutics, a public biopharmaceutical company.

What is Jeffrey Robert Ajer's net worth?

The estimated net worth of Jeffrey Robert Ajer is at least $4.92 million as of April 8th, 2021. Mr. Ajer owns 58,250 shares of BioMarin Pharmaceutical stock worth more than $4,919,213 as of January 20th. This net worth evaluation does not reflect any other investments that Mr. Ajer may own. Learn More.

How do I contact Jeffrey Robert Ajer?

The corporate mailing address for Mr. Ajer and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected]

Has Jeffrey Robert Ajer been buying or selling shares of BioMarin Pharmaceutical?

Jeffrey Robert Ajer has not been actively trading shares of BioMarin Pharmaceutical in the last ninety days. Most recently, Jeffrey Robert Ajer sold 2,739 shares of the business's stock in a transaction on Tuesday, October 26th. The shares were sold at an average price of $73.60, for a transaction totalling $201,590.40.

Who are BioMarin Pharmaceutical's active insiders?

BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Jean Bienaime (CEO), George Davis (EVP), Richard Meier (Director), and Brian Mueller (CFO).

Are insiders buying or selling shares of BioMarin Pharmaceutical?

In the last twelve months, insiders at the biotechnology company sold shares 22 times. They sold a total of 135,546 shares worth more than $10,892,217.87. The most recent insider tranaction occured on January, 14th when Director V Bryan Lawlis sold 4,250 shares worth more than $372,342.50. Insiders at BioMarin Pharmaceutical own 1.7 % of the company.

Information on this page was last updated on 1/14/2022.

Jeffrey Robert Ajer Insider Trading History at BioMarin Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/26/2021Sell2,739$73.60$201,590.40View SEC Filing Icon  
4/8/2021Sell1,537$78.81$121,130.9758,250View SEC Filing Icon  
3/24/2021Sell1,181$76.30$90,110.3061,439View SEC Filing Icon  
3/18/2021Sell1,308$77.99$102,010.9264,133View SEC Filing Icon  
10/14/2020Sell2,121$79.91$169,489.1161,281View SEC Filing Icon  
6/19/2020Sell15,000$124.00$1,860,000.0063,402View SEC Filing Icon  
4/8/2020Sell2,407$79.98$192,511.8663,064View SEC Filing Icon  
4/1/2020Sell1,537$82.00$126,034.0065,471View SEC Filing Icon  
3/24/2020Sell2,041$74.36$151,768.7668,626View SEC Filing Icon  
3/21/2019Sell4,519$89.98$406,619.6256,659View SEC Filing Icon  
3/19/2019Sell3,728$93.07$346,964.9659,248View SEC Filing Icon  
11/14/2018Sell9,000$92.15$829,350.0058,135View SEC Filing Icon  
10/3/2018Sell1,000$98.98$98,980.0049,135View SEC Filing Icon  
6/11/2018Sell1,436$90.31$129,685.1650,135View SEC Filing Icon  
5/7/2018Sell309$85.96$26,561.6453,223View SEC Filing Icon  
4/2/2018Sell2,119$80.12$169,774.2852,914View SEC Filing Icon  
3/29/2018Sell1,537$79.69$122,483.5355,033View SEC Filing Icon  
3/21/2018Sell4,368$83.90$366,475.2060,153View SEC Filing Icon  
3/9/2018Sell2,972$82.39$244,863.0855,332View SEC Filing Icon  
9/22/2017Sell3,521$95.00$334,495.0049,299View SEC Filing Icon  
6/7/2017Sell1,004$89.61$89,968.4447,944View SEC Filing Icon  
5/2/2017Sell302$96.74$29,215.4851,834View SEC Filing Icon  
3/29/2017Sell3,890$89.15$346,793.5051,532View SEC Filing Icon  
3/7/2017Sell5,000$90.56$452,800.0046,510View SEC Filing Icon  
9/27/2016Sell18,467$95.61$1,765,629.8741,342View SEC Filing Icon  
5/3/2016Sell415$86.03$35,702.4563,487View SEC Filing Icon  
3/4/2016Sell1,255$88.42$110,967.1048,137View SEC Filing Icon  
7/20/2015Sell3,000$150.00$450,000.00View SEC Filing Icon  
6/4/2015Sell1,362$122.35$166,640.70View SEC Filing Icon  
6/1/2015Sell377$123.76$46,657.52View SEC Filing Icon  
5/26/2015Sell1,625$126.55$205,643.75View SEC Filing Icon  
11/3/2014Sell47$83.54$3,926.38View SEC Filing Icon  
5/16/2014Sell1,004$56.91$57,137.6420,980View SEC Filing Icon  
5/13/2013Sell1,248$69.26$86,436.48View SEC Filing Icon  
See Full Table

Jeffrey Robert Ajer Buying and Selling Activity at BioMarin Pharmaceutical

This chart shows Jeffrey Robert Ajer's buying and selling at BioMarin Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
Read More

Today's Range

Now: $84.45
Low: $84.26
High: $87.49

50 Day Range

MA: $86.73
Low: $80.74
High: $91.47

2 Week Range

Now: $84.45
Low: $71.59
High: $92.17

Volume

863,821 shs

Average Volume

1,564,464 shs

Market Capitalization

$15.50 billion

P/E Ratio

1,055.63

Dividend Yield

N/A

Beta

0.49
Bezos, Elon Musk and Zuckerberg Betting Big on S.C.G.
The "Black Box" Device Bringing the Age of the Smartphone to an End.
Learn More